Curcumin in combined cancer therapy

Current Pharmaceutical Design

Volumn 20, Issue 42, 2014, Pages 6682-6696

  Troselj, Koraljka Gall ^a   Kujundzic, Renata Novak ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cancer; Cancer chemoresistance; Combined cancer therapy; Curcumin; Inflammation; NF B

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CURCUMIN; CYTOSTATIC AGENT; DNA METHYLTRANSFERASE 1; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MUCIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLON CANCER; CONSERVATIVE TREATMENT; CYTOPLASM; DNA BINDING; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG TOLERABILITY; EXPERIMENTAL NEOPLASM; GENE SILENCING; HUMAN; INFLAMMATION; NONHUMAN; PANCREAS CANCER; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; CURCUMA; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CURCUMA; CURCUMIN; HUMANS; NEOPLASMS; NF-KAPPA B;

EID: 84911498908     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826154601     Document Type: Article

References (165)

1. Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr 2008; 17: 265-8.
2. Schraufstatter E, Bernt H. Antibacterial action of curcumin and related compounds. Nature 1949; 164: 456.
3. Muller KH, Honerlagen H. A method for the determination of curcumin in drugs. Arzneimittelforschung 1959; 9: 134.
4. Roth HJ, Miller B. On the color reaction between boric acid and curcumin. I. Boric acid-curcumin complexes. Arch Pharm (Wein-heim) 1964; 297: 617-23.
5. Oppenheimer A. Turmeric (curcumin) in biliary diseases. Lancet 1937; 229: 619-21.
6. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010; 62: 919-30.
7. Adapala N, Chan MM. Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model. Lab Invest 2008; 88: 1329-39.
8. Marathe SA, Sen M, Dasgupta I, Chakravortty D. Differential modulation of intracellular survival of cytosolic and vacuolar pathogens by curcumin. Antimicrob Agents Chemother 2012; 56: 5555-67.
9. Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976; 25: 1811-2.
10. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepato-toxic principles of Curcuma longa rhizomes. Planta Med 1983; 49: 185-7.
11. Zhang DM, Li YC, Xu D, Ding XQ, Kong LD. Protection of cur-cumin against fructose-induced hyperuricaemia and renal endothelial dysfunction involves NO-mediated JAK-STAT signalling in rats. Food Chem 2012; 134: 2184-93.
12. Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 2010; 61: 247-52.
13. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998; 124: 425-7.
14. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. Thromb Res 1985; 40: 413-7.
15. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-4.
16. Sivak A, Van Duuren BL. Phenotypic expression of transformation: induction in cell culture by a phorbol ester. Science 1967; 157: 1443-4.
17. Blumberg PM, Leach KL, König B, Jeng AY, Sharkey NA. Receptors for the phorbol ester tumour promoters. Ciba Found Symp 1985; 116: 205-23.
18. Ren L, Hong SH, Cassavaugh J, et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC. Oncogene 2009; 28: 792-802.
19. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988; 48: 5941-6.
20. Huang MT, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cy-clooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813-9.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
23. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000; 248: 171-83.
24. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-67.
25. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.
26. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
27. Zabel U, Baeuerle PA. Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA. Cell 1990; 61: 255-65.
28. Beg AA, Baldwin AS Jr. The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors. Genes Dev 1993; 7: 2064-70.
29. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12: 695-708.
30. Razani B, Reichardt AD, Cheng G. Non-canonical NF-κB signaling activation and regulation: principles and perspectives. Immunol Rev 2011; 244: 44-54.
31. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85-98.
32. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189: 1839-45.
33. Qing G, Qu Z, Xiao G. Stabilization of basally translated NF-jB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-κB2 p100. J Biol Chem 2005; 280: 40578-82.
34. Xiao G, Fong A, Sun S-C. Induction of p100 processing by NF-κB-inducing kinase involves docking IkB kinase a (IKKa) to p100 and IKKα-mediated phosphorylation. J Biol Chem 2004; 279: 30099-105.
35. Chen FE, Ghosh G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. Oncogene 1999; 18: 6845-52.
36. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011; 12: 715-23.
37. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med 2006; 79: 123-30.
38. Narisawa T, Satoh M, Sano M, Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983; 4: 1225-7.
39. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
40. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
41. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
42. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004; 4: 29-42.
43. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5.
44. Hull MA, Booth JK, Tisbury A, et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999; 79: 1399-405.
45. Kalgutkar AS, Crews BC, Rowlinson SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cy-clooxygenase-2. Science 1998; 280: 1268-70.
46. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
47. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60.
48. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
49. Vaish V, Rana C, Piplani H, Vaiphei K, Sanyal SN. Sulindac and celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. Cell Biochem Biophys 2014; 68: 301-19.
50. Labayle, D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9.
51. Steinbach G, Lynch PM, Phillips RK, et al. The effect of Cele-coxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
52. Brady RR, Loveridge CJ, Dunlop MG, Stark LA. c-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells. Carcinogenesis 2011; 32: 1069-77.
53. Loveridge CJ, MacDonald AD, Thoms HC, Dunlop MG, Stark LA. The proapoptotic effects of sulindac, sulindac sulfone and indo-methacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene 2008; 27: 2648-55.
54. Khandelwal N, Simpson J, Taylor G, et al. Nucleolar NF-κB/RelA mediates apoptosis by causing cytoplasmic relocalization of nu-cleophosmin. Cell Death Differ 2011; 18: 1889-903.
55. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274: 27307-14.
56. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006; 25: 6800-16.
57. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995-5000.
58. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
59. Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723-7.
60. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxy-genase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315-20.
61. Das KC, White CW. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997; 272: 14914-20.
62. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999; 163: 3474-83.
63. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999; 20: 445-51.
64. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 2000; 60: 1665-76.
65. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med 2012; 52: 2013-37.
66. Lin CL, Lin JK. Curcumin: a potential cancer chemopreventive agent through suppressing NF-κB signaling. J Cancer Mol 2008; 4: 11-6.
67. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcu-min, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
68. Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006; 6: 10.
69. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol 2007; 595: 471-80.
70. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
71. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14: 120-5.
72. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
73. Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G. Curcumin--from molecule to biological function. Angew Chem Int Ed Engl 2012; 51: 5308-32.
74. Novak Kujundzić R, Grbesa I, Ivkić M, Katdare M, Gall-Troselj K. Curcumin downregulates H19 gene transcription in tumor cells. J Cell Biochem 2008; 104: 1781-92.
75. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64: 353-6.
76. Helson L. Curcumin (diferuloylmethane) delivery methods: a review. Biofactors 2013; 39: 21-6.
77. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5: 3.
78. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: A review of pharmaceutical properties and pre-clinical studies and clinical data related to cancer treatment. Biomaterials 2014; 35: 3365-83.
79. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 2011; 34: 660-5.
80. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 2013; 71: 1521-30.
81. Vitaglione P, Barone Lumaga R, et al. Curcumin bioavailability from enriched bread: the effect of microencapsulated ingredients. J Agric Food Chem 2012; 60: 3357-66.
82. Fatih N, Camberlein E, Island ML, et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl) 2010; 88: 477-86.
83. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 2014; 58: 516-27.
84. Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005; 11: 6738-44.
85. Shpitz B, Giladi N, Sagiv E, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74: 140-4.
86. Carroll RE, Benya RV, Turgeon DK, et al Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011; 4: 354-64.
87. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188: 21-8.
88. Tan X, Poulose EM, Raveendran VV, Zhu BT, Stechschulte DJ, Dileepan KN. Regulation of the expression of cyclooxygenases and production of prostaglandin I2 and E2 in human coronary artery endothelial cells by curcumin. J Physiol Pharmacol 2011; 62: 21-8.
89. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004; 25: 1671-9.
90. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapop-totic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004; 13: 853-65.
91. Saleh, EM, El-awady RA, Eissa NA, Abdel-Rahman WM. Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways. Cancer Biol Ther 2012; 13: 1058-71.
92. Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear fac-tor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 607-16.
93. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007; 102: 157-72.
94. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-7.
95. Anto RJ, Maliekal TT, Karunagaran D. L-929 cells harboring ec-topically expressed RelA resist curcumin-induced apoptosis. J Biol Chem 2000; 275: 15601-4.
96. Chuang SE, Yeh PY, Lu YS, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 2002; 63: 1709-16.
97. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 2002; 51: 211-8.
98. Aota K, Azuma M, Yamashita T, et al. 5-Fluorouracil induces apoptosis through the suppression of NF-kappaB activity in human salivary gland cancer cells. Biochem Biophys Res Commun 2000; 273: 1168-74.
99. Shakibaei M, Mobasheri A, Lueders C, Busch F, Shayan P, Goel A. Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. PLoS One 2013; 8: e57218.
100. Kunnumakkara AB, Diagaradjane P, Anand P, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009; 125: 2187-97.
101. Srimuangwong K, Tocharus C, Tocharus J, Suksamrarn A, Chin-tana PY. Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats. World J Gastroenterol 2012; 18: 6951-9.
102. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its de-methoxy and hydrogenated derivatives. Biol Pharm Bull 2007; 30: 74-8.
103. Srimuangwong K, Tocharus C, Yoysungnoen Chintana P, Suksam-rarn A, Tocharus J. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 2012; 18: 2383-9.
104. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gem-citabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-61.
105. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcit-abine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007; 25: 411-8.
106. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcit-abine: can genetic studies lead to tailor-made therapy? Br J Cancer 2007; 97: 145-51.
107. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011; 378: 607-20.
108. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-45.
109. Kanai M, Yoshimura K, Asada M, et al. A phase I/II study of gem-citabine-based chemotherapy plus curcumin for patients with gem-citabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011; 68: 157-64.
110. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G. Cur-cumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010; 62: 1137-41.
111. Jonckheere N, Skrypek N, Merlin J, et al. The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways. PLoS One 2012; 7: e32232.
112. Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I, Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 2013; 32: 1714-23.
113. Breier A, Barancík M, Sulová Z, Uhrík B. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457-68.
114. Chen KG, Sikic BI. Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res 2012; 18: 1863-9.
115. Bentires-Alj M, Barbu V, Fillet M, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90-7.
116. Zatelli MC, Molè D, Tagliati F, Minoia M, Ambrosio MR, degli Uberti E. Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell Oncol 2009; 31: 457-65.
117. Kanagasabai R, Krishnamurthy K, Druhan LJ, Ilangovan G. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem 2011; 286: 33289-300.
118. Schäfer C, Seeliger H, Bader DC, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med 2012; 16: 1776-91.
119. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 2007; 31: 1345-50.
120. Kuramitsu Y, Suenaga S, Wang Y, et al. Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells. Anticancer Res 2013; 33: 3 133-6.
121. Mori-Iwamoto S, Taba K, Kuramitsu Y, et al. Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine. Pancreas 2009; 38: 224-6.
122. Parcellier A, Schmitt E, Gurbuxani S, et al. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 2003; 23: 5790-802.
123. Soler C, Felipe A, García-Manteiga J, et al. Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and-independent signalling pathways. Biochem J 2003; 375: 777-83.
124. Bayet-Robert M, Morvan D. Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcu-min alone and in association with docetaxel. PLoS One 2013; 8(3): e57971.
125. Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res 2013; 5: 357-65.
126. Yang F, Teves SS, Kemp CJ, Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 2014; 1845: 84-9.
127. Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y, Sonobe T. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm 2012; 432: 42-9.
128. Qian H, Yang Y, Wang X. Curcumin enhanced adriamycin-induced human liver-derived hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci 2011; 43: 125-31.
129. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activa tion levels and in IAP gene expression. Cancer Lett 2005; 224: 53-65.
130. Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 2012; 44: 73-7.
131. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993; 43: 527-33.
132. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoro-pyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-201.
133. Koo JY, Kim HJ, Jung KO, Park KY. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fuorouracil. J Med Food 2004; 7: 117-21.
134. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006; 52: 23-8.
135. Vinod BS, Antony J, Nair HH, et al. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis 2013; 4: e505.
136. Howells LM, Mitra A, Manson MM. Comparison of oxaliplatin-and curcumin-mediated antiproliferative effects in colorectal cell lines. Int J Cancer 2007; 121: 175-83.
137. Patel BB, Gupta D, Elliott AA, Sengupta V, Yu Y, Majumdar AP. Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30: 319-25.
138. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11: 7490-8.
139. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007; 104: 13-9.
140. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005; 280: 6301-8.
141. Bava SV, Sreekanth CN, Thulasidasan AK, et al. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 2011; 43: 331-41.
142. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 2011; 30: 3139-52.
143. Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J 2010; 277: 3437-48.
144. Zhan Y, Chen Y, Liu R, Zhang H, Zhang Y. Potentiation of pacli-taxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharm Res 2013 Dec 10, in press, DOI 10. 1007/s12272-013-0311-3.
145. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010; 9: 8-14.
146. Gilbert CA, Ross AH. Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem 2009; 108: 1031-8.
147. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
148. Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci 2007; 10: 19-26.
149. Cheng L, Wu Q, Guryanova OA, et al. Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun 2011; 406: 643-8.
150. Kiefel H, Pfeifer M, Bondong S, Hazin J, Altevogt P. Linking L1CAM-mediated signaling to NF-κB activation. Trends Mol Med 2011; 17: 178-87.
151. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 123: 2135-43.
152. Yoon H, Min JK, Lee DG, Kim DG, Koh SS, Hong HJ. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett 2012; 316: 70-6.
153. Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P, Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 2007; 104: 461-9.
154. Hossain M, Banik NL, Ray SK. Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int2012; 61: 1102-13.
155. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2009; 2: 321-8.
156. Nautiyal J, Kanwar SS, Yu Y, Majumdar AP. Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. J Mol Signal. 2011; 6: 7.
157. Liu Z, Xie Z, Jones W, et al. Curcumin is a potent DNA hy-pomethylation agent. Bioorg Med Chem Lett 2009; 19: 706-9.
158. Du L, Xie Z, Wu LC, et al. Reactivation of RASSF1A in breast cancer cells by curcumin. Nutr Cancer 2012; 64: 1228-35.
159. Yu J, Peng Y, Wu LC, et al. Curcumin down-regulates DNA meth-yltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS One 2013; 8: e55934.
160. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 2008; 68: 5345-54.
161. Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46-53.
162. Lee JY, Lee YM, Chang GC, et al. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS One 2011; 6: e23756.
163. Lai HW, Chien SY, Kuo SJ, et al. The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: An in vitro and in vivo comparison study with herceptin. Evid Based Complement Alternat Med 2012; 2012: 486568.
164. Galmarini CM, Tredan O, Galmarini FC. Concomitant resistance and early-breast cancer: should we change treatment strategies? Cancer Metastasis Rev 2013, in press, DOI 10. 1007/s10555-013-9449-1.
165. Bobrovnikova-Marjon EV, Marjon PL, Barbash O, Vander Jagt DL, Abcouwer SF. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res 2004; 64: 4858-69.